Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Res Int ; 2015: 574086, 2015.
Article in English | MEDLINE | ID: mdl-26078956

ABSTRACT

Breast cancer is one of the most common malignant diseases occurring in women, and its incidence increases over the years. It is the main site of origin in ocular metastatic disease in women, and, due to its hematogenous nature of metastatic spread, it affects mainly the uveal tissue. The purpose of this paper is to summarize the clinical manifestations of the breast cancer ocular metastatic disease, alongside the side effects of the available treatment options for the management and regression of the systematic and ophthalmic disease.


Subject(s)
Breast Neoplasms/pathology , Drug-Related Side Effects and Adverse Reactions/physiopathology , Eye Neoplasms/pathology , Breast Neoplasms/drug therapy , Eye Neoplasms/secondary , Female , Humans
2.
BMC Cancer ; 9: 338, 2009 Sep 23.
Article in English | MEDLINE | ID: mdl-19775466

ABSTRACT

BACKGROUND: Targeting angiogenesis is nowadays one of the most promising approaches for breast cancer. Bevacizumab (BEV), a VEGF-trap monoclonal antibody, was recently approved in combination with paclitaxel (PAC) for the first line treatment of advanced breast cancer (ABC). The activity of this combination in pretreated patients is not known. METHODS: Patients with pretreated ABC and progressive disease received BEV 10 mg/kg with PAC 135 mg/m(2) every two weeks for six months and then maintenance with BEV 15 mg/kg every three weeks until progression. This regimen was chosen for better patient convenience, while maintaining the same dose intensity for both drugs. RESULTS: 42 patients were reviewed retrospectively (41 f, 1 m, mean age 57 years). Overall response rate was 35.7%. Stable disease was observed in 45.2% of patients, whereas 14.3% of patients progressed. The median overall survival was greater than 20 months, with a one year rate of 83.4%. The median progression free survival was 12.1 months, with a one year rate of 51.8%. Toxicity was in general acceptable. CONCLUSION: This biweekly BEV/PAC combination seems to be active with acceptable toxicity in pretreated ABC with an advantage over the weekly regimen regarding quality of life and preservation of resources.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Breast Neoplasms, Male/therapy , Breast Neoplasms/therapy , Paclitaxel/administration & dosage , Salvage Therapy , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized , Bevacizumab , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Breast Neoplasms, Male/drug therapy , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Paclitaxel/adverse effects , Retrospective Studies , Survival
SELECTION OF CITATIONS
SEARCH DETAIL
...